CA2827052C - Anti-alpha-v integrin antibody for the treatment of prostate cancer - Google Patents

Anti-alpha-v integrin antibody for the treatment of prostate cancer Download PDF

Info

Publication number
CA2827052C
CA2827052C CA2827052A CA2827052A CA2827052C CA 2827052 C CA2827052 C CA 2827052C CA 2827052 A CA2827052 A CA 2827052A CA 2827052 A CA2827052 A CA 2827052A CA 2827052 C CA2827052 C CA 2827052C
Authority
CA
Canada
Prior art keywords
use according
administration
antibody
patients
di17e6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827052A
Other languages
English (en)
French (fr)
Other versions
CA2827052A1 (en
Inventor
Axel Hoffmann
Heinrich LANNERT
Klaus Brischwein
Frederic Christian PIPP
Juergen REINDL
Karin GROLL
Michael ZUEHLSDORF
Otmar PFAFF
Sabine RAAB
Ulrike DAU
Benoit Destenaves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2827052A1 publication Critical patent/CA2827052A1/en
Application granted granted Critical
Publication of CA2827052C publication Critical patent/CA2827052C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2827052A 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer Active CA2827052C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11001135.0 2011-02-11
EP11001135 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
CA2827052A1 CA2827052A1 (en) 2012-08-16
CA2827052C true CA2827052C (en) 2022-08-16

Family

ID=45569571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827052A Active CA2827052C (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Country Status (23)

Country Link
US (3) US9555110B2 (https=)
EP (2) EP3415162A1 (https=)
JP (2) JP6320042B2 (https=)
KR (2) KR102103701B1 (https=)
CN (1) CN103347540B (https=)
AU (2) AU2012216145B2 (https=)
CA (1) CA2827052C (https=)
DK (1) DK2672994T3 (https=)
EA (1) EA032117B1 (https=)
ES (1) ES2683347T3 (https=)
HR (1) HRP20181212T1 (https=)
HU (1) HUE037212T2 (https=)
IL (1) IL227687B (https=)
LT (1) LT2672994T (https=)
MX (2) MX352025B (https=)
PL (1) PL2672994T3 (https=)
PT (1) PT2672994T (https=)
RS (1) RS57524B1 (https=)
SG (1) SG192667A1 (https=)
SI (1) SI2672994T1 (https=)
TR (1) TR201810294T4 (https=)
WO (1) WO2012107211A1 (https=)
ZA (1) ZA201306807B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
ES2856348T3 (es) 2014-09-17 2021-09-27 Merck Patent Gmbh Un método para el tratamiento de cánceres sólidos y/o metástasis de los mismos, medicamentos relacionados, y un método para la predicción de la evolución clínica del tratamiento de cánceres sólidos y/o metástasis de los mismos
EP3194972B1 (en) * 2014-09-17 2021-04-14 Merck Patent GmbH A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
BR112018010337A2 (pt) * 2015-11-23 2018-12-04 Merck Patent Gmbh anticorpo anti-alfa-v integrina para o tratamento de fibrose e/ou transtornos fibróticos
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
KR20110140143A (ko) 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
RU2390353C2 (ru) 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2008008435A2 (en) 2006-07-14 2008-01-17 Rutgers, The State University Methods, systems, and compositions for extracellular matrix production
DK2167128T3 (da) * 2007-07-17 2012-12-03 Merck Patent Gmbh Fremstillede anti-alfa-v-integrin hybrid-antistoffer
WO2009026328A2 (en) 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
ES2622487T3 (es) 2009-08-19 2017-07-06 Merck Patent Gmbh Anticuerpos para la detección de complejos de integrina en material FFPE
AU2010318323A1 (en) 2009-11-13 2012-06-28 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
WO2011162933A1 (en) 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
WO2012107211A1 (en) 2011-02-11 2012-08-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Also Published As

Publication number Publication date
MX385144B (es) 2025-03-14
US20140086908A1 (en) 2014-03-27
ES2683347T3 (es) 2018-09-26
EP2672994A1 (en) 2013-12-18
KR20190044696A (ko) 2019-04-30
JP6488273B2 (ja) 2019-03-20
KR101972533B1 (ko) 2019-08-26
WO2012107211A1 (en) 2012-08-16
MX352025B (es) 2017-11-07
AU2017200998A1 (en) 2017-03-09
HUE037212T2 (hu) 2018-08-28
MX2013009062A (es) 2013-10-01
US20190263913A1 (en) 2019-08-29
JP2017066156A (ja) 2017-04-06
CN103347540A (zh) 2013-10-09
PT2672994T (pt) 2018-10-22
LT2672994T (lt) 2018-07-25
US9555110B2 (en) 2017-01-31
AU2012216145A1 (en) 2013-09-26
ZA201306807B (en) 2014-05-28
PL2672994T3 (pl) 2018-11-30
EA201391147A1 (ru) 2014-01-30
CA2827052A1 (en) 2012-08-16
AU2012216145B2 (en) 2016-11-17
CN103347540B (zh) 2016-05-25
DK2672994T3 (en) 2018-07-16
US20170218070A1 (en) 2017-08-03
HRP20181212T1 (hr) 2018-10-05
SG192667A1 (en) 2013-09-30
TR201810294T4 (tr) 2018-08-27
EP3415162A1 (en) 2018-12-19
JP2014510047A (ja) 2014-04-24
EP2672994B1 (en) 2018-05-09
KR102103701B1 (ko) 2020-04-23
IL227687A0 (en) 2013-09-30
AU2017200998B2 (en) 2018-08-09
KR20140012087A (ko) 2014-01-29
IL227687B (en) 2019-02-28
JP6320042B2 (ja) 2018-05-09
RS57524B1 (sr) 2018-10-31
SI2672994T1 (sl) 2018-09-28
EA032117B1 (ru) 2019-04-30
HK1190094A1 (zh) 2014-06-27

Similar Documents

Publication Publication Date Title
US11866509B2 (en) Humanized antibodies against CEACAM1
US20190263913A1 (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
JP4364510B2 (ja) 受容体型チロシンキナーゼ阻害剤および血管新生阻害剤を用いる併用療法
US12398209B2 (en) Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP2003520195A (ja) 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
CN101588812A (zh) 使用整联蛋白配体治疗癌的特异疗法和药物
JP2012528079A (ja) 癌を治療するためのインテグリンリガンドの連続投与
KR20210095139A (ko) 전이성 췌장 선암종의 치료 방법
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
HK1190094B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
WO2025238587A1 (en) Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025245256A1 (en) Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323